NCT05633563View on ClinicalTrials.gov

The Effect of Trimetazidine on Mitochondrial Function, Myocardial Performance, and Invasive Hemodynamics in Patients Diagnosed With Wild-Type Transthyretin Cardiac Amyloidosis

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 1, 2021

Primary Completion Date

June 1, 2023

Study Completion Date

June 1, 2023

Conditions

Transthyretin Amyloid CardiopathyMitochondrial Pathology

Interventions

DRUG

Trimetazidine

Oral intake of capsules

DRUG

Placebo

Oral intake of capsules

Trial Locations (1)

8200

Aarhus University Hospital, Department of Cardiology, Aarhus N

All Listed Sponsors

lead

Steen Hvitfeldt Poulsen

OTHER

NCT05633563 - The Effect of Trimetazidine on Mitochondrial Function, Myocardial Performance, and Invasive Hemodynamics in Patients Diagnosed With Wild-Type Transthyretin Cardiac Amyloidosis | Biotech Hunter | Biotech Hunter